Clinical Trial Update: A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD [Phase 2]

View source ↗

Summary

Phase 2 trial comparing a depot formulation of sunitinib malate (GB-102) versus aflibercept in neovascular AMD has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• GB-102 (sunitinib malate depot formulation) (sunitinib malate)

Snippet

Sponsor: Graybug Vision | Conditions: Neovascular Age-Related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2022-01-11